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Summary
A disturbed methylation has been proposed as a mechanism via
which homocysteine is associated with diseases like vascular dis-
ease, neural tube defects and mental disorders. Catechol-
O-methyltransferase (COMT) is involved in the S-adenosyl-
methionine-dependent methylation of catecholamines and cate-
cholestrogens and in this way contributes to homocysteine syn-
thesis. COMT dysfunction has been related to schizophrenia
and breast cancer.We hypothesized that COMT dysfunction by
virtue of functional genetic polymorphisms may affect plasma
total homocysteine (tHcy). Our primary objective was to study
the association between common COMT polymorphisms and
tHcy. Secondly, we evaluated these polymorphisms as a risk fac-
tor for recurrent venous thrombosis. We obtained genotype
data from four polymorphisms in the COMT gene (rs2097603,
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rs4633, rs4680 [324G>A] and rs174699) from 401 population-
based controls.We performed haplotype analysis to investigate
the association between common haplotypes and tHcy. In addi-
tion, we assessed the rs4680 variant as a genetic risk factor in a
case-control study on recurrent venous thrombosis (n= 169).
We identified a common haplotype that was significantly associ-
ated with tHcy levels.This effect was largely explained by the
rs4680 variant, resulting in an increase in tHcy of 10.4% (95% CI
0.01 to 0.21, p=0.03) for 324AA compared with 324GG sub-
jects. Interestingly,we found that the 324AA genotype was more
common in venous thrombosis patients (OR 1.61 [95% CI 0.97
to 2.65], p=0.06) compared to control subjects.We show that
the COMT rs4680 variant modulates tHcy, and might be associ-
ated with venous thrombosis risk as well.
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Introduction
A disturbed homocysteine metabolism has been associated with
diseases of the vascular system, both of arterial and venous ori-
gin (1–3). In addition, high plasma total homocysteine (tHcy) in-
creases the risk of spina bifida, and mental disorders like schizo-
phrenia and Alzheimer’s disease (4–6). The mechanism of how
homocysteine is related to disease is still obscure (7), but there
are strong indications that a disturbed transmethylation may
partly explain this association (8–11). Several studies show that
plasma total homocysteine levels (tHcy) correlate well with plas-
ma S-adenosylhomocysteine (AdoHcy) (12, 13), a strong in-
hibitor of S-adenosylmethionine (AdoMet)-dependent methyl-
ation. Given the importance of methylation of nucleic acids, pro-
teins, lipids (8, 10, 14, 15), but also hormones and neurotrans-
mitters (16, 17), it seems plausible that the inhibition or dysfunc-
tion of specific methyltransferases affect critical processes and
hence confer a higher risk of disease.
The enzyme Catechol-O-methyltransferase (COMT, E.C.
2.1.1.6) is one of the methyltransferases that is highly susceptible
to inhibition by AdoHcy (18). COMT represents a major pathway
in the degradation of catecholamine neurotransmitters, like dopa-
mine and (nor)adrenaline, and catecholestrogens. Hence, COMT
dysfunction has been implicated in complex diseases like schizo-
phrenia, Parkinson’s disease and breast cancer (17, 19–21).
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COMT enzyme exists as a membrane-bound (MB) and sol-
uble (S) isoform, the expression of which is regulated by two dif-
ferent promoters. A common 324G>A polymorphism (rs4680)
in the COMT gene, resulting in a valine-to-methionine substitu-
tion at position 108 (S-isoform) and 158 (MB-isoform), has been
studied extensively for its effect on enzyme activity and ex-
pression, although the data is non-consistent (22, 23).
The metabolic pathways of COMT and homocysteine are in-
terconnected as the O-methylation of catecholamines and cate-
cholestrogens catalyzed by COMT produces homocysteine (Fig.
1).Therefore, functional variants within the COMT gene may in-
fluence tHcy levels and possibly reflect disturbed transmethyl-
ation capacity implicated in COMT-related diseases. This is il-
lustrated by the fact that we did find an interaction between
MTHFR and COMT in relation to schizophrenia risk (25).
The primary objective of our study was to investigate the ef-
fect of genetic variations within the COMT gene on tHcy by
means of haplotype analysis. Considering the controversy
whether the 324G>A variant is causally related to decreased
enzyme activity or expression, we included three other variants
(rs2097603) [22], rs4633 and rs174699) in or directly adjacent to
the COMT gene in our analyses. Secondly we evaluated these-
polymorphisms as a risk factor for recurrent venous thrombosis.
Material and methods
Subjects used in the present study
The study group was recruited via a general practice in The
Hague, the Netherlands, and has been described in more detail
elsewhere (25). Recurrent venous thrombosis cases were se-
lected from the files of the anticoagulant clinic in Leyenburg
Hospital in The Hague, The Netherlands, and control subjects
were recruited via a general practice; pregnancy was the only ex-
clusion criterion. For the current association study, DNA was
available from 438 control subjects and 169 recurrent venous
thrombosis patients. With these numbers we had power of 50 to
78% to detect a difference of 10 to 15% in tHcy (two sided
α=0.05).The power to detect an effect of COMT genotype on ve-
nous thrombosis was 54%.
Biochemical parameters
Blood samples were drawn after an overnight fast from the ante-
cubital vein in 5 ml Vacutainer tubes and 4.5 ml EDTA vacuum
glass tubes for determination of total plasma homocysteine and
for DNA extraction. EDTA samples for homocysteine measure-
ment were placed on ice immediately and centrifuged at 3,500 g
for 5 minutes (min) with minimal delay. The plasma was separ-
ated and then stored at –20ºC. Total plasma homocysteine con-
centrations were measured by an automated high-performance
liquid chromatography method with reverse phase separation
and fluorescent detection (Gilson 232–401 sample processor,
Spectra Physics 8800 solvent delivery system and LC 304 fluor-
ometer) (26). DNA extraction was performed as described pre-
viously (27), and the DNA was stored at 4ºC.
Genotype analysis
We genotyped four single nucleotide polymorphisms (SNPs)
distributed over the gene of interest: rs2097603, rs4633, rs4680
(sometimes referred to as rs165688) and rs174699. The SNPs
were chosen based on frequency, functionality and location with-
in the gene. All four created or abolished an enzyme restriction
site allowing a simple screening based on restriction-fragment
length polymorphism (RFLP) analysis. Screening conditions
were similar in all analyses. For details see Table 1. PCR condi-
tions: 4 min at 94°C, 35 cycles of 94°C/60 seconds (s),
52–60°C/60 s, and 72°C/30 s, and a final extension of 7 min at
72°C. Each PCR reaction mixture contained 50 ng of both for-
ward and reverse primer (Biolegio BV, The Netherlands),
200 µM dNTPs, 10 mM Tris-HCl buffer (pH 8.2), 50 mM KCl,
2.0–4.0 mM MgCl
2
, 0.5 U of recombinant Taq polymerase, 5%
DMSO (Invitrogen, The Netherlands) and 75 ng DNA. The re-
sulting PCR product was digested by at least 10 units of restric-
tion enzyme (all from New England Biolabs, Inc.) and incubated
for 3 hours or overnight at 37°C. The digests were analyzed by
gel electrophoresis on a 3% or 4% agarose gel, stained with
ethidiumbromide and visualized by UV. In all PCR amplifi-
cations and restriction analyses, DNA samples from which the
genotype had been identified by sequence analysis served as
positive controls. From 401 population-based controls, genotype
data was available for all four SNP’s (although the total number
of genotyped individuals were different for each polymorphism).
Figure 1: Simplified representation of
homocysteine metabolism and the lo-
cation of Catechol-o-methyltransferase
(COMT) enzyme within this metabolism.
Abbreviations: Met, methionine; AdoMet,
S-adenosylmethionine; AdoHcy, S-adenosyl-
homocysteine; Hcy, homocysteine; MS, Me-
thionine Synthase; THF, tetrahydrofolate;
MTHFR, methylenetetrahydrofolate reductase.
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In addition, data of four other reported variants (i.e. rs6267
[Ala22Ser] [28], rs740602, rs13306281 and rs3218737) was ob-
tained from 150 subjects from the same population by means of
sequence analysis using the ABI Prism 3130XL automated se-
quencer according to the instructions of the manufacturer (Ap-
plied Biosystems, The Netherlands). However, three of them ap-
peared non-polymorphic, while rs740602 was found only once
in the heterozygous state (minor allele frequency of <0.01) and
all were excluded from further analysis. For the case-control
study, genotype data (rs4680) from 169 cases with a history of
venous thrombosis was obtained.
Statistical analyses
Haploview (29) was used to evaluate linkage disequilibrium (LD)
and correlations between the SNPs. Haplotype association ana-
lyses for homocysteine levels were performed using Whap. Whap
(http://pngu.mgh.harvard.edu/purcell//whap) takes the ambi-
guity in individual haplotype estimations into account by apply-
ing a weighted likelihood approach. Prior to the haplotype ana-
lyses, the log transformed Hcy values were standardized. We used
permutation testing as implemented in the Whap program to cor-
rect for multiple testing in all analyses. Haplotypes with a fre-
quency of less than 2% were excluded from the analysis. Single-
locus genotype effects on (log-transformed) metabolites were
evaluated by linear regression analysis (SPSS 12.0). In the haplo-
Table 1: Baseline characteristics of pa-
tients with recurrent venous thrombosis
and control subjects*.
Variable Cases
(n = 185)
Controls
(n = 500)
P-value
Age (year) 062 (42–79) 050 (34–69) <0.01
Sex (men) 094 (51%) 208 (42%) 0.03
Post-menopausal women 064 (35%) 138 (28%) <0.01
Time between 1
st
event and study (years) 017 (range 1 to 58) - -
Time between last event and study (years) 007 (range 1 to 30) - -
Type of venous thrombosis
– Only pulmonary embolism (PE)
– Only deep vein thrombosis (DVT)
– Both DVT and PE
043
073
069
- -
Smoking (yes/no) 061 (33%) 167 (34%) 0.9
Folate (nM) 013.5 (7.7–23.5) 012.7 (7.0–23.6) 0.2
Vitamin B12 (µM) 241 (118–466) 217 (125–389) 0.04
Vitamin B6 (nM) 025.8 (12.7–55.7) 027.6 (15.7–54.8) 0.03
Vitamin B2 (nM) 010.2 (4.9–37.1) 009.1 (4.0–25.9) 0.07
FactorV Leiden (MAF)
†
014.6% 003.3% <0.01
Prothrombin G20210A (MAF)
†
002.9% 001.6% 0.12
MTHFR C677T (MAF)
†
033.3% 029.1% 0.21
*Data are given as medians with 10
th
to 90
th
percentiles in parenthesis for continuous variables and as numbers with perecentages in
parenthesis for categorical variables,
†
MAF= minor allele frequency.
B-vitamin (yes/no) 023 (12%) 076 (15%) 0.9
Homocysteine (µΜ) 012.2 (8.3–20.8) 010.7 (6.7–15.5) <0.01
Creatinine (µM) 081 (61–112) 074 (55–99) <0.01
Table 2: Relevant data of analyzed polymorphisms and method of screening.
Variant Reported
MAF
a
DNA Protein
b
HW P-
value
[Mg
2+
]
(mM)
T
ann
(°C)
rs2097603 0.39 (G) 5’ region A>G
(P2 promoter)
- 0.87 2.0 52
rs4633 0.39 (T) 36T>C H12H 0.52 4.0 60
rs4680 0.36–0.52 (A) 324G>A V108M 0.40 2.0 59
rs174699 0.19 (C) Intron 3 T>C - 1.0 3.0 59
a
MAF, minor allele frequency (source: NCBI),
b
amino acid change using the (short) soluble form as reference,
c
Hardy-Weinberg (HW) p-value.
Primers (5’à 3’)
F aatttggctattgccgtgtc
R gtcccataaaaggggattcg
F acaacctgctcatgggtgac
R tcctgtaagggctttgatgc
F tactgtggctactcagctgtgc
R gtgaacgtggtgtgaacacc
F cctctgtgaggctccaactc
R gaaagaaggcagcacctgtc
Validation
method
+HindIII
+PmlI
+NlaIII
-NcoI
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type analysis, changes in homocysteine levels are expressed
relative to the most frequent haplotype group. Odds ratios (ORs)
were estimated using logistic regression analysis (SPSS 12.0).
Results
Population charateristics and genotyping
Baseline characteristics of the study populations are shown in
Table 1.
For details about these SNPs regarding location, function and
validation method, see Table 2. The four COMT SNPs under
study were all in Hardy-Weinberg equilibrium (p>0.4). Minor al-
lele frequencies for rs2097603, rs4633, rs4680 and rs174699
were 0.48 (G allele), 0.47 (C allele), 0.49 (G allele) and 0.068 (C
allele), respectively. Of note, the 324G allele (which is presumed
to be the wild-type allele of rs4680) had a lower frequency than
the 324A allele, which is also observed in other studies (Table 2).
Linkage disequilibrium (D’) and squared correlation coefficients
between each of the genotyped variants are shown in Table 3. The
SNP pair rs4680 (324G>A) and rs4633 (36T>C) was in almost
complete LD, with a D’ of 0.96 and a squared correlation (r
2
) of
0.89. No strong LD was observed for the other SNP pairs.
Haplotype associations in the general population
Genotype data for all four polymorphisms was obtained from
401 individuals (mean age 50.6 ± 13.3 years), from which 41.0%
was male (n=164). Mean fasting tHcy was 10.4 (95% CI 10.0 to
10.8) µM, serum creatinin was 74.3 (95% CI 72.7 to 75.9) µM,
vitamin B12 was 221 (95% CI 208 to 234) pM and folate was
13.1 (95% CI 12.3 to 13.9) nM. tHcy was correlated with plasma
folate, red blood cell folate and vitamin B12 (Spearmann ρ valu-
es were –0.21, –0.24 and –0.31, respectively, with p<0.01 at a
two-tailed level).
The haplotype frequencies and their relative effects on tHcy are
presented in Table 4. By omitting the haplotypes with a frequency
of less than two percent, 95% of the haplotypes was covered. The
omnibus association test using all haplotypes for crude fasting
tHcy showed a bordeline significant effect (p=0.05). Haplotype
specific analysis, i.e. analysis of the effect of the haplotype relative
to the most common haplotype, showed that the effect was mainly
due to the G-C-G-T haplotype that was statistically significant as-
sociated with low tHcy levels (-13.3% [95% CI –23.6 to –3.1],
p=0.01). Adjustment for age, sex, serum creatinine, MTHFR
677C>T polymorphism and plasma folate did not change this point
estimate (not shown). The omnibus haplotype test was no longer
significant when the analysis was conducted conditional on rs4680
or on rs4633 (p=0.28 and p=0.26, respectively).This means that the
haplotype analysis did not reveal major additional effects besides
that observed for the single-loci. Indeed, an increase of 10.4%
(95% CI 0.01 to 0.21, p=0.03) and 8.8% (95% CI –0.00 to 0.18,
p=0.06) in tHcy was observed for COMT 324AA and 324GA (rs
4680) individuals, respectively, when compared with 324GG sub-
jects (Table 5). None of the genotypes was associated with folate,
red blood cell folate or vitamin B12 levels (not shown). Moreover,
the fact that adjustment for folate status (an important determinant
of tHcy) did not influence the association between the COMT ha-
plotype and tHcy suggests that the observed genotype-phenotype
association is not confounded by differences in vitamin status.
Furthermore, by comparing a model in which the effects of
the three haplotypes containing allele C and G at the second and
third locus were constrained to be equal to a model in which all
haplotype effects were estimated separately, we found that the ef-
fects of the N-C-G-N haplotypes (where N represents one of the
alleles observed at the first and fourth locus) were not different
(p=0.18). This suggests that the haplotype background on which
these variants appear had no major influence on tHcy.
The COMT 324G>A variant and recurrent venous
thrombosis risk
Genotype data of the COMT 324G>A (rs4680) polymorphism
was obtained from 424 controls and 169, from which 41%
(n=174) and 51% (n=86) were male, respectively. For the con-
trols, mean age and blood parameters were similar as those indi-
viduals included in the haplotype analysis. For the recurrent ve-
nous thrombosis cases (mean age 61.5 ± 14.3 years) geometric
mean (95% CI) tHcy was 12.6 (11.6 to 13.6) µM, 83.1 (78.6 to
87.6) µM for serum creatinin, 237 (207 to 267) pM for vitamin
B12 and 13.7 (12.4 to 15.0) nM for folate.
The genotype frequencies were 34.9% (n=59), 45.6%
(n=77), 19.5% (n=33), and 27.6% (n=117), 47.6% (n=202),
24.8% (n=105) forAA,AG, GG genotypes in cases and controls,
Table 3: Linkage disequilibrium coef-
ficient (D’) between SNPs across the
COMT gene in controls. Above the diagonal
the D’-values are shown and below the diagon-
al their corresponding squared correlation co-
efficients (in italics).
Variant Rs number rs2097603 rs4633 rs4680 rs174699
1 rs2097603 - 0.427 0.438 0.50
2 rs4633 0.149 - 0.964 0.627
3 rs4680 0.165 0.89 - 0.695
4 rs174699 0.016 0.033 0.038 -
Distance from
rs2097603 (bp)
00000
22143
23179
26366
Haplotype Frequency Crude change tHcy % [95% CI]
G-T-A-T 0.355 0
a
A-C-G-T 0.312 –3.2 [-9.7 to 3.4]
A-T-A-T 0.167 1.3 [-7.3 to 9.8]
G-C-G-T 0.120 –13.3 [-23.6 to –3.1]
b
A-C-G-C 0.046 –3.3 [-15.8 to 9.2]
a
Reference category,
b
p-ANOVA = 0.01.
Table 4: Haplotype frequencies and relative change in tHcy in
the general population using the G-T-A-T haplotype (cor-
responding with SNP 1, 2, 3 and 4, respectively) as a reference.
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respectively.These correspond to minor (G) allele frequencies of
0.42 and 0.49 for cases and controls, respectively. We found that
individuals with the 324AA genotype, corresponding with those
having the highest tHcy, were at higher risk for recurrent venous
thrombosis compared with 324GG subjects, although this esti-
mation did not reach statistical significance (OR 1.61 [95%CI
0.97 to 2.65], p=0.06). The OR for individuals with the 324GA
genotype was 1.21 (95% CI 0.76 to 1.94, p=0.18).The other gen-
etic variants were not associated with recurrent venous thrombo-
sis risk (not shown)
Discussion
We screened for the rs4680 variant as well as three other SNPs
dispersed over the COMT gene (rs2097603, rs4633 and
rs174699) and performed haplotype analysis in order to identify
whether a specific haplotype was related to tHcy. We show that
rs4680 was singularly associated with tHcy levels in a Dutch
population study, and was responsible for the observed haplo-
type effect. The small, but non-significant, effect on tHcy that
was observed for variant rs4633 (not shown) is likely to be ex-
plained by its high correlation with rs4680 (Table 2) (20, 30). In-
terestingly, the 324AA genotype (rs4680) was more prevalent in
venous thrombosis cases suggesting that this variant may affect
recurrent venous thrombosis risk as well.
The 324G>A (rs4680) polymorphism has been extensively
studied for its effect at the molecular level, mostly because of its
potential role in schizophrenia susceptibility. Functional studies
showed that the COMT 324AA genotype is associated with de-
creased enzyme activity in vitro and in human brain extracts (22,
31) although theVal-allele was expressed at a slightly lower level
in human brain (23). In the past, Goodman et al. (19) showed that
the COMT 324G>A variant affected tHcy in controls, while Gei-
sel et al. did not find such an effect in elderly subjects (32). In ad-
dition, it has been suggested that other variants might explain the
observed associations (20). Our results show that the 324AA ge-
notype is significantly associated with increased tHcy levels,
which may support the observation of higher expression of the
Met-allele by Bray et al. (23). The higher levels of tHcy associ-
ated with the 324AA genotype may explain why these subjects
tend to have a higher risk for venous thrombosis. However, a dis-
turbed methylation by COMT in itself may also be involved, es-
pecially since the vascular system is constantly exposed to circu-
lating catecholamines and catecholestrogens. It has been shown
that catecholestrogens may have beneficial effects on the vascu-
lar system by reducing fibrinogen and overall fibrinolysis poten-
tial (33), although negative effects have also been reported (16).
The measurement of plasma AdoMet and AdoHcy levels, the
ratio of which is a marker of methylation capacity, and in-vitro
methylation studies could provide additional evidence for dis-
turbed methylation in subjects carrying this variant. It should be
noted that we included patients with a history of venous throm-
bosis, which may give an overestimation of the relative risk. Ad-
ditional studies are required to study whether the COMT
324G>A polymorphism is related to a first thrombotic event.
One may raise the question whether it is plausible that the
flux through the COMT enzyme is high enough to generate a
relatively large difference in tHcy (about 10%) between subjects
having the 324GG and 324AA genotype. Studies with Parkin-
son’s disease patients whose tHcy levels rose upon L-DOPA
treatment (34–36), indicate that a higher COMT flux is reflected
in plasma tHcy levels. In addition, a recent genome-wide linkage
scan performed by Souto et al. identified another methyltransfe-
rase, Nicotinamide N-methyltransferase (NNMT), as a possible
major determinant of tHcy (37).This shows that not only methyl-
transferases with a high flux-rate, like guanidinoacetate- and
phosphatidylethanolamine methyltransferase (15), contribute to
homocysteine synthesis, but also methyltransferases with an ap-
parently modest contribution to overall methyltransferase activ-
ity. In conclusion, the 324AA genotype (rs4680) is associated
with increased tHcy in the general population. Subjects with the
324AA genotype also tend to have a higher risk for recurrent ve-
Variant Genotype n (%) MAF
b
Crude mean tHcy
[95% CI] (µM)
Crude change %
[95% CI]
P-value
rs2097603 AA 117 (27.7) 10.7 [10.0 to 11.5] 00
a
(n=422) AG 208 (49.3) 10.3 [9.8 to 10.8] –4.1 [-12.1 to 4.7]
GG 097 (23.0) 0.48 (G) 10.3 [9.5 to 11.1] –4.2 [-13.6 to 6.3] 0.474
rs4633 TT 120 (29.1) 10.8 [10.4 to 11.5] 00
a
(n=413) TC 199 (48.2) 10.4 [9.9 to 11.0] –3.0 [-11.0 to 5.6]
CC 094 (22.8) 0.47 (C) 10.0 [9.2 to 10.8] –7.3 [-16.3 to 2.6] 0.143
rs4680 GG 105 (24.8) 0.49 (G) 09.6 [8.7 to 10.7] 00
a
(n=424) GA 202 (47.6) 10.5 [9.6 to 11.5] 08.8 [-0.00 to 0.18]
AA 117 (27.6) 10.8 [10.0 to 11.5] 10.4 [0.01 to 0.21] 0.036
rs174699 TT 365 (86.9) 10.4 [10.0 to 10.8] 00
a
(n=420) TC 053 (12.6) 10.2 [9.2 to 11.3] –2.4 [-12.7 to 9.1]
CC 002 (0.5) 0.07 (C) 10.7 [6.3 to 18.3] 02.8 [-39.8 to 75.1] 0.748
a
reference category,
b
MAF, minor allele frequency.
Table 5: COMT single-locus genotype effects on tHcy concentrations in population-based controls.
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